The complexity of initiating clinical studies continues to grow. The complexity is a confluence of complicated protocols, globalization, and regulatory changes, all at a time when there is intense pressure to restrain costs and shorten timelines. The key to reducing these complexities is the ability to use machine learning to gain critical operational insights, which will allow organizations to learn and adapt. The insights gained will allow organizations to transition from subjective decisions to data-driven decisions.
In October 2020, Ed Miseta had the opportunity to sit down with four experts on the topic of AI/machine learning to gain a better understanding of the technology. In this segment, Nechama Katan of Pfizer and Alex Zhavoronkov of Insilico Medicine discuss the human problem involved with bringing AI into clinical trials.